8-K current report · filed Nov 9, 2026

Foghorn Therapeutics Inc. (FHTX) 8-K Current Report: November 9, 2026

Item 2.02Item 7.01Item EX-99.1Item EX-99.2FHTX overview

Short answer

Foghorn Therapeutics Inc. (FHTX) filed an 8-K current report with the SEC on November 9, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item 7.01 (Regulation FD Disclosure), Item EX-99.1 (Exhibit EX-99.1), Item EX-99.2 (Exhibit EX-99.2). Q3 2026 financial results for the quarter ended September 30, 2026 announced.

Foghorn Therapeutics Inc. 8-K event analysis

AI summary of each reported item and its exhibits

Item 2.02 · Results of Operations and Financial Condition

  • Q3 2026 financial results for the quarter ended September 30, 2026 announced
  • Press release contains the substantive financial figures and operating updates
  • Investor focus: cash position, operating expenses, pipeline progress and financing runway in Exhibit 99.1

Item 7.01 · Regulation FD Disclosure

  • November 2026 investor presentation furnished as Exhibit 99.2
  • Presentation likely contains updated company, pipeline, or strategic information for investor meetings

Item EX-99.1 · Exhibit EX-99.1

  • Q3 2026 collaboration revenue $83.5M vs $8.2M, including $74.1M cumulative catch-up from discontinued FHD-909 and SMARCA2 programs
  • Net income $58.2M, or $0.80 diluted EPS, vs $15.8M loss and $0.25 loss per share in Q3 2025
  • Cash, equivalents and marketable securities $156.2M, supporting runway into second half of 2029
  • IBD program entering dose-range studies in Q4 2026, with potential first-in-human trials by end of 2027
  • Selective EP300 degrader targeting an IND in 2027, focused on multiple myeloma and DLBCL

Item EX-99.2 · Exhibit EX-99.2

  • Investor presentation outlines wholly owned pipeline spanning oncology, I&I, and induced-proximity programs
  • Cash and equivalents $156.2M as of 09/30/2026, supporting runway into second half of 2029
  • Selective EP300 degrader: IND targeted in 2027 for multiple myeloma and DLBCL
  • Oral IBD small molecule: drug research formulation initiation in Q4 2026, FIH studies targeted by end of 2027
  • Approximately 71.8M shares outstanding, including pre-funded warrants, as of 09/30/2026

Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean

Other Foghorn Therapeutics Inc. 8-K filings

Get the next FHTX 8-K as it lands

Follow FHTX for push alerts, or ask the research agent what this filing means.